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Abstract
The relationship between in vivo synaptic density and molecular pathology in primary 
tauopathies is key to understanding the impact of tauopathy on functional decline and in 
informing new early therapeutic strategies. In this cross-sectional observational study, we 
determine the in vivo relationship between synaptic density and molecular pathology, in the 
primary tauopathies of Progressive Supranuclear Palsy (PSP) and Corticobasal Degeneration 
(CBD), as a function of disease severity. Twenty three people with PSP, and twelve people 
with Corticobasal Syndrome (CBS) were recruited from a tertiary referral centre. Nineteen 
education, sex and gender-matched control participants were recruited from the National 
Institute for Health Research ‘Join Dementia Research’ platform. Cerebral synaptic density 
and molecular pathology, in all participants, were estimated using PET imaging with the 
radioligands [11C]UCB-J and [18F]AV-1451, respectively. Patients with CBS also underwent 
amyloid PET imaging with [11C]PiB to exclude those with likely Alzheimer’s pathology – we 
refer to the amyloid negative cohort as having CBD although acknowledge other pathologies 
exist. Disease severity was assessed with the PSP rating scale; regional non-displaceable 
binding potentials (BPND) of [11C]UCB-J and [18F]AV-1451 were estimated in regions of 
interest from the Hammersmith Atlas, excluding those with known off-target binding for  
[18F]AV-1451. As an exploratory analysis, we also investigated the relationship between 
molecular pathology in cortical brain regions, and synaptic density in subcortical areas. 
Across brain regions, there was a positive correlation between [11C]UCB-J and [18F]AV-1451 
BPND (ß = 0.4, t = 3.6, p = 0.001), independent of age or time between PET scans. However, 
this correlation became less positive as a function of disease severity in patients (ß = - 0.02, t 
= -2.9, p = 0.007, R = -0.41). Between regions, cortical [18F]AV-1451 binding was negatively 
correlated with synaptic density in subcortical areas (caudate nucleus, putamen). Brain 
regions with higher synaptic density are associated with a higher [18F]AV-1451 binding in 
PSP/CBD, but this association diminishes with disease severity. Moreover, higher cortical 
[18F]AV-1451 binding correlates with lower subcortical synaptic density. Longitudinal 
Page 1 of 40 Brain
© The Author(s) (2021). Published by Oxford University Press on behalf of the Guarantors of Brain. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, 







ab282/6353021 by guest on 26 August 2021
imaging is required to confirm the mediation of synaptic loss by molecular pathology. 
However, the effect of disease severity suggests a biphasic relationship between synaptic 
density and molecular pathology with synapse-rich regions vulnerable to accrual of 
pathological aggregates, followed by a loss of synapses in response to pathology. Given the 
importance of synaptic function for cognition, our study elucidates the pathophysiology of 
primary tauopathies and may inform the design of future clinical trials.
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Introduction
Synaptic loss is a feature of many neurodegenerative disorders 1-3. It is closely related to 
cognitive decline in symptomatic stages of disease 4, 5, but can begin long before symptom 
onset and neuronal loss 6. Synaptic loss and dysfunction may be an important mediator of 
decline even where atrophy is minimal or absent 7, 8. Conversely, synaptic connectivity may 
facilitate the spread of oligomeric mis-folded proteins such as tau 9-14. The relationship between 
synaptic loss and the accumulation of mis-folded proteins in primary tauopathies has yet to be 
determined in vivo. Preclinical models suggest early synaptotoxicity of oligomeric tau, leading 
to reduced synaptic plasticity and density 15, 16. In patients with mutations of microtubule-
associated protein tau (MAPT), there are deficiencies in many synaptic pathways including 
GABA-mediated signalling and synaptic plasticity 17. The mechanisms of synapse loss 
following tau pathology include both direct and indirect pathways (reviewed in Spires-Jones 
and Hyman 18), however, the severity of synaptic toxicity in the related tauopathy of 
Alzheimer’s disease appears to be dependent on the stage of disease in preclinical models, and 
in patients post-mortem and in vivo. In animal models of Alzheimer’s disease, and at human 
post-mortem, there is differential expression of synaptic proteins in the early stages with 
increases in some proteins and reductions in others 19, 20. This may be an attempt to maintain 
cellular physiology in early disease, which fails as the disease progresses, leading to loss of 
synaptic function and synapse numbers in moderate and advanced disease. In clinical disorders, 
the in vivo pathologies of synaptic density and tau burden can be characterised by positron 
emission tomography (PET). Recent in vivo PET imaging in Alzheimer’s disease using 
[11C]UCB-J as a marker of synaptic density and [18F]AV-1451 or [18F]MK-6240 PET as 
markers of tau pathology have shown decreased temporal lobe synaptic density with increasing 
pathological burden 21, but with individual variability depending on the severity of cortical 
pathology 22. However, the pathology of Alzheimer’s disease is multifaceted with amyloid and 
tau aggregation, vascular changes and neuroinflammation 23. 
In this study, we use Progressive Supranuclear Palsy - Richardson’s syndrome (PSP) 24 and 
Corticobasal Degeneration (CBD) 25  as models of human tauopathy, with relevance to other 
tau-mediated neurodegenerative disorders, and examine the in vivo relationship between 
synaptic density and burden of molecular pathology. An advantage of studying PSP is the very 
high correlation between the clinical syndrome, and the specific 4R-tauopathy at autopsy 26, 27. 
The clinical phenotype of Corticobasal Syndrome (CBS), may be caused by CBD, but can also 
be mimicked by Alzheimer’s disease, and less commonly by other forms of frontotemporal 
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lobar degeneration. Here, we use the term CBD to refer to patients with CBS in whom 
Alzheimer’s disease is excluded by [11C]PiB PET, whereby in the absence of amyloid pathology 
there is a high clinicopathological correlation with 4R-tauopathy at post-mortem. Both PSP and 
CBD demonstrate synaptic loss in vivo 7, 8 and at post-mortem 1, 2. The distribution of tau 
pathology in both diseases is well characterised with cortical and subcortical involvement 28, 29. 
Animal models of tauopathy have illustrated the co-localisation of tau aggregates at the synaptic 
bouton, associated with synaptic dysfunction and synaptic loss 18, 30 but the tau-synapse 
association is yet to be determined in vivo. [18F]AV-1451 signals are above normal in the cortex 
of patients with PSP and CBS/CBD 31-37 but there is relatively low affinity for 4R-tauopathy 
compared to Alzheimer’s disease, and off-target binding particularly in the basal ganglia. We 
therefore refer to [18F]AV-1451 as a marker of ‘molecular pathology’, referring to the 
combination of tau and non-tau targets.
Figure 1 illustrates our hypotheses. Previous studies suggest that the strength of connectivity 
within a region and between brain regions can promote the spread of tau pathology, in humans 
as in preclinical models 9-14. Therefore, we hypothesised that brain areas with higher synaptic 
density would develop more tau pathology (schematically represented by green arrows in 
Figure 1A). We predicted that the spatial distribution of molecular pathology, as measured with 
the PET radioligand [18F]AV-1451, would be correlated with synaptic density, as measured 
with the PET radioligand [11C]UCB-J (which binds to the presynaptic vesicle glycoprotein 
SV2A that is ubiquitously expressed in brain synapses 38, 39). Since pathology in a region may 
impair efferent projections, a corollary hypothesis is that tau accumulation in one region (source 
region) leads to diaschisis characterised by reduced synaptic density in the areas to which it 
connects (target regions). 
A second part of the model describes the consequence of the pathology, which is to reduce 
synaptic density (schematically represented by red arrows in Figure 1A). The predicted result 
is a positive relationship between [18F]AV-1451 binding and synaptic loss, negatively 
moderated by disease severity (Figure 1B). 
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Materials and Methods
Participant recruitment and study design 
Twenty-three people with probable PSP–Richardson Syndrome, and twelve people with 
probable CBS in whom Alzheimer’s disease was excluded with [11C]PiB PET, were recruited 
from a regional specialist National Health Service clinic at the Cambridge University Centre 
for Parkinson-plus. We refer to our amyloid-negative CBS cohort as having CBD but 
acknowledge other pathologies are possible. Nineteen healthy volunteers were recruited from 
the UK National Institute for Health Research Join Dementia Research (JDR) register. 
Participants were screened using the inclusion/exclusion criteria set out in Holland et al. 20208. 
Eligible participants underwent clinical and cognitive assessments (Table 1) including the 
revised Addenbrooke’s Cognitive Examination (ACE-R), the mini-mental state examination 
(MMSE), and the Institute of Cognitive Neurology (INECO) frontal screening; disease severity 
was measured with the PSP rating scale, and the Cortical Basal ganglia Functional Scale 
(CBFS) 40. Participants underwent 3T MRI, [18F]AV-1451 PET, and [11C]UCB-J PET. The 
research protocol was approved by the Cambridge Research Ethics Committee (reference 
18/EE/0059) and the Administration of Radioactive Substances Advisory Committee. All 
participants provided written informed consent in accordance with the Declaration of Helsinki. 
PET data acquisition and kinetic analysis 
[11C]UCB-J PET
The procedure for [11C]UCB-J synthesis, PET data acquisition, image reconstruction and 
kinetic analysis was the same as in Holland et al. 2020. In brief, dynamic PET data acquisition 
was performed on a GE SIGNA PET/MR (GE Healthcare, Waukesha, USA) for 90 minutes 
immediately after injection, with attenuation correction using a multi-subject atlas method 41 
and improvements to the MRI brain coil component 42. Emission image series were aligned 
using SPM12 (www.fil.ion.ucl.ac.uk/spm/software/spm12/), and rigidly registered to the T1-
weighted MRI acquired during PET data acquisition (TR = 3.6 msec, TE = 9.2 msec, 192 
sagittal slices, in plane resolution 0.55 x 0.55 mm, interpolated to 1.0 x 1.0 mm; slice thickness 
1.0 mm). The Hammersmith atlas (http://brain-development.org) with modified posterior fossa 
regions was spatially normalized to the T1-weighted MRI of each participant using Advanced 
Normalisation Tools (ANTs) software 43. Regional time-activity curves were extracted 
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following the application of geometric transfer matrix (GTM) partial volume correction (PVC 
44) to each dynamic PET image. Regions of interest (ROIs) were multiplied by a binary grey 
matter mask (>50% on the SPM12 grey matter probability map smoothed to PET spatial 
resolution), with the exception of the subcortical grey matter regions pallidum, substantia nigra, 
pons and medulla. To assess the impact of PVC, time-activity curves were also extracted from 
the same ROIs without the application of GTM PVC (discussed below as “without partial 
volume correction”).
To quantify SV2A density, [11C]UCB-J non-displaceable binding potential (BPND) was 
determined using a basis function implementation of the simplified reference tissue model 45, 
with the reference tissue defined in the centrum semiovale 46, 47. 
[18F]AV-1451 PET
As for [11C]UCB-J, PET data acquisition was performed on a GE SIGNA PET/MR for 90 
minutes after [18F]AV-1451 injection, with attenuation correction as described above for 
[11C]UCB-J. Image processing was also as given above for [11C]UCB-J, except that [18F]AV-
1451 BPND was determined using a different basis function implementation of the simplified 
reference tissue model 48 and the reference tissue was defined in inferior cerebellar grey matter 
using a 90% threshold on the grey matter probability map produced by SPM12 smoothed to 
PET resolution.
[11C]PiB PET 
Amyloid imaging using Pittsburgh Compound B ([11C]PiB) followed the protocol given in 
Holland et al. 2020 8. [11C]PiB cortical standardised uptake value ratio (SUVR; 50-70 minutes 
post injection) was calculated using the whole cerebellum reference tissue as per the Centiloid 
Project methodology 49. A negative amyloid status was characterised by a cortical [11C]PiB 
SUVR less than 1.21 obtained by converting the Centiloid cut-off of 19 to SUVR using the 
Centiloid-to-SUVR transformation in Jack et al. 2017 50. 
Statistical analyses
We compared demographic and clinical variables between the diagnostic groups using 
ANCOVA, and chi-square tests where appropriate. We used a linear mixed effects model to 
assess the overall relationship between [18F]AV-1451 and [11C]UCB-J BPND, with age and scan 
interval as covariates. To adjust for normal levels of tracer uptake from off-target binding not 
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present in the reference region (over and above the correction for non-specific binding in the 
reference region), we normalised the patient BPND data against controls by subtracting the 
regional mean BPND values in controls from the data of each patient, for each region, for each 
tracer. Furthermore, we removed regions with previously reported off-target binding of 
[18F]AV-1451 (basal ganglia, and substantia nigra 51). The linear mixed effect model therefore 
included, normalised [11C]UCB-J as the dependent variable, normalised [18F]AV-1451 as the 
independent variable, and age and scan interval as covariates of no interest. To investigate the 
effect of individual variability on the relationship between [11C]UCB-J and [18F]AV-1451 
BPND, we used a linear model with the slope of [11C]UCB-J BPND as a function of [18F]AV-
1451 BPND for each individual (extracted from the previous linear mixed effect model) as the 
dependent variable, and the PSP rating scale (a measure of disease severity) as the independent 
variable, and age as a covariate of no interest. To explore the correlation between [11C]UCB-J 
and [18F]AV-1451 BPND between regions, we calculated a correlation matrix between cortical 
[18F]AV-1451 binding and synaptic density in cortical and subcortical regions. 
Analyses were performed with and without GTM partial volume correction, yielding similar 
results; we focus on partial volume corrected BPND to limit the potential effect of atrophy on 
our ligand cross-correlation but present data without partial volume correction in the 
supplementary material. Statistical analyses were implemented in R (version 3.6.2).
Data Availability Statement 
The data that support the findings of this study are available from the corresponding author, 
upon reasonable request for academic (non-commercial) purposes, subject to restrictions 
required to preserve participant confidentiality.  
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Results
Demographics
The patients (PSP and CBD) and control groups were similar in age, sex, education and injected 
activity of [11C]UCB-J and [18F]AV-1451 (Table 1).  We observed typical cognitive profiles 
for people with PSP and CBD: impaired on verbal fluency, memory and visuospatial domains 
of the ACE-R and MMSE, and the INECO frontal screening tool.
Relationship between [11C]UCB-J BPND and [18F]AV-1451 BPND 
Compared to controls, patients had significantly higher [18F]AV1451 binding in the caudate 
nucleus, pallidum, putamen, and substantia surviving correction for multiple comparison (p< 
0.05, False Discovery Rate (FDR) corrected) (Supplementary Figure 1A, Supplementary Table 
2). As previously reported in a smaller cohort 7, 8, patients had significantly lower [11C]UCB-J 
binding across all cortical and subcortical areas compared to controls, which survived FDR 
correction (Supplementary Figure 1B, Supplementary Table 4). Summary statistics for regional 
[18F]AV1451 and [11C]UCB-J binding potentials in patients and controls are shown in 
Supplementary Tables 1 and 3, respectively. 
There was an overall positive relationship between normalised [18F]AV-1451 BPND and 
[11C]UCB-J BPND across the patient cohort (ß=0.4, t=3.6, p=0.001) (Figure 2A). There was a 
significant region-by-[18F]AV-1451 interaction (p<0.001) driven by subregions of the frontal, 
parietal, and temporal cortices, as well as the hippocampus, subcallosal area, and the thalamus, 
with all but the hippocampus surviving correction for multiple comparison. Age (p = 0.9) and 
scan interval (p = 0.5) did not have a significant effect on the overall model (NB: brain regions 
with known off-target binding of [18F]AV-1451 were removed before running this linear mixed 
model). The direction of the relationship between [18F]AV-1451 BPND and [11C]UCB-J BPND 
within each individual (i.e. the slope of each grey line in Figure 2A) negatively correlated with 
disease severity (ß = - 0.02, t = -2.9, p = 0.007, R = -0.41), independent of age (effect of age: 
=0.02,  t=2.6, p= 0.01) (Figure 2B). In other words, those patients with more severe disease 
displayed a less positive relationship between [18F]AV-1451 BPND and [11C]UCB-J BPND. 
Of note, the positive correlation between [18F]AV-1451 BPND and [11C]UCB-J BPND across the 
patient cohort remains even if BPND values are not normalised against the control data (ß=0.4, 
t=4.0, p=0.0001), as well as the negative relationship between disease severity and the slope 
of each individual in Figure 2A. Also note that very similar findings were observed using BPND 
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derived from data without partial volume correction (Supplementary Figure 2). 
The relationship between [18F]AV-1451 and [11C]UCB-J binding was also positive in an 
analogous linear mixed effect model in controls alone (=0.6, t=4, p<0.0001), with no main 
effect of age or scan interval, or [18F]AV-1451-by-Region interaction. The relationship 
between unadjusted [18F]AV-1451 and [11C]UCB-J binding in all three groups (controls, 
amyloid negative CBS and PSP) is shown in Supplementary Figure 3. 
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Cross-regional correlation between [18F]AV-1451 BPND and 
[11C]UCB-J BPND 
Synaptic density in a region is proposed to be affected by both local tau pathology and tau 
burden in connected regions from which it receives afferent projections. As a result, despite a                                                        
positive correlation at a regional level, the synaptic density in any given region may be 
negatively affected by remote insult, with diaschisis between anatomically connected regions 
(illustrated schematically in Figure 1A).  As an exploratory analysis, we computed the 
asymmetric Pearson’s correlation matrix shown in Figure 3, between normalised cortical 
[18F]AV-1451 BPND (horizontal axis of matrix) and normalised cortical and subcortical 
[11C]UCB-J BPND  (vertical axis of matrix) in patients. We show that overall, there are 
significant negative correlations between cortical (frontal, temporal, parietal, occipital) 
[18F]AV-1451 BPND and subcortical [11C]UCB-J BPND within the caudate nucleus and putamen 
(-0.52 < R < -0.37; p < 0.05; uncorrected for multiple comparisons). We observed a positive 
correlation between [18F]AV-1451 BPND   and [11C]UCB-J BPND within the thalamus where 
strong local connections exist (Figure 3). We did not include subcortical [18F]AV-1451 BPND  
in the matrix in Figure 3 given the off-target binding in these regions which undermines the 
interpretability of the signal. However, we include these regions as well as other subregions in 
the larger correlation matrix in Supplementary Figure 4 for completeness.  Similar findings are 
seen using BPND from data without partial volume correction (Supplementary Figure 5).    
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Discussion
We have identified an in vivo relationship between molecular pathology (estimated with 
[18F]AV-1451 PET) and synaptic density (estimated with [11C]UCB-J PET), in patients with 
the primary tauopathies of Progressive Supranuclear Palsy and Corticobasal Degeneration 
(inferred in vivo from amyloid-negative corticobasal syndrome). There are three principal 
results: (i) regions with higher synaptic density have higher molecular pathology, (ii) within 
regions, synaptic density becomes less dependent on [18F]AV-1451 binding as disease severity 
increases, and (iii) between regions, increased cortical [18F]AV-1451 binding is associated with 
reduced subcortical synaptic density. We interpret these three findings in the context of synaptic 
connectivity-based susceptibility to tauopathy, the synaptotoxic effects of tauopathy, and 
cortico-subcortical diaschisis, respectively. The above results are congruent with the model of 
tau-induced synaptic toxicity, acknowledging the caveat of off-target binding of [18F]AV-1451. 
Our primary pathology of interest in the context of PSP and CBD is 4R-tau, but other 
tauopathies such as latent Alzheimer pathology in older adults, and non-tau molecular 
pathologies may also contribute to [18F]AV-1451 binding. 
The effect of hyperphosphorylated tau on synaptic function and density is complex. It involves 
both direct and indirect pathways of injury with changes in cellular physiology preceding the 
loss of neurons. Through direct pathways, pathological tau interferes with dendritic 
morphology, synaptic protein expression, the number of NMDA (N-methyl-D-Aspartate) and 
AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptors on the pre-
synaptic membrane, mitochondrial function, synaptic vesicle numbers, and ultimately synaptic 
loss (for a review of animal studies illustrating various direct tau-induced synaptic 
abnormalities see Jadhav et al. 2015 52). Tau also directly affects the axon cytoskeleton and 
trafficking, as well as the normal functioning of the soma 53. Indirectly, hyperphosphorylated 
tau adversely affects the functioning of the neuronal support network, including glia cells and 
astrocytes 54-56. These events are affected by the stage and severity of the disease process, and 
in relation to regional differences in connectivity which we discuss next (concepts 
schematically illustrated in Figure 1). 
We identified a positive relationship between the binding of [11C]UCB-J and [18F]AV-1451 
such that areas of the brain with higher synaptic density had higher pathology. This accords 
with preclinical and clinical models of tauopathy in which the strength of local network 
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connectivity facilitates the transneuronal spread of tau pathology 9, 12, 57-59. 
However, the relationship between tau accumulation and synaptic density changes with disease 
progression, at least as inferred from the cross-sectional moderation by disease severity (Figure 
2B). With increasing scores on the PSP rating scale, synaptic density becomes less dependent 
on local accumulation of pathology. In other words, according to the model (see Figure 1) in 
areas with relatively low tau accumulation synaptic density is minimally affected, whereas in 
areas with higher tau accumulation there is reduction of synaptic density as the disease 
progresses; and this preferentially occurs in synapse rich areas. As the disease progresses, other 
pathological processes may contribute to synaptic loss, such as inflammation, another predictor 
of prognosis and mediator of synaptic loss 60. There is therefore not a simple linear relationship 
between tau accumulation and synaptic density in moderate and advanced disease. This 
observation accords with human post-mortem and animal studies. In post-mortem studies of 
the tauopathy Alzheimer’s disease, there is a biphasic synaptic protein response during disease 
progression, with increases in synaptophysin/syntaxin/SNAP-25 in early Braak stages and 
synaptic loss observed only when the disease has progressed to the neocortex 19. In the P301L 
transgenic mouse model of PSP-like tauopathy, there is a differential loss of synapses, as well 
as synaptic proteins, depending on disease stage 20. These results have recently been replicated 
in vivo, where the relationship between synaptic density and tau burden in patients with 
Alzheimer’s disease is reported to be modulated by cortical tau load. Coomans  et al. show that 
in patients with mild disease and low cortical tau burden, the relationship between tau and 
synaptic density is positive, whereas in those with increasing cortical tau load, this relationship 
changes direction 22; the relationship between the two tracers in controls is not reported.  
In our study, we also observe a positive relationship between [18F]AV-1451 and [11C]UCB-J 
binding potentials in controls (Supplementary Figure 3), even though [18F]AV-1451 binding is 
lower in controls. Disease-related [18F]AV-1451 binding attributable to presence of PSP/CBD 
pathology is unlikely in the controls, as the prevalence of these conditions in the normal 
population is only 1/10,000 61. However, the presence of asymptomatic Alzheimer’s disease 
pathology in the normal older population is more likley. Rising from the age of 40, by the age 
of 85 two-thirds of cognitively normal individuals will show positive changes in the A/T/N 
classification for Alzheimer’s disease, whether by CSF, plasma or amyloid PET 62, 63. Some of 
the non-specific [18F]AV-1451 signal, even in healthy controls, may therefore be attributable 
to latent/pre-clinical AD pathology. We control for this component of the signal by subtracting 
the mean regional control values from those of the patients. 
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The positive correlation between [18F]AV-1451 and [11C]UCB-J binding potential in controls 
appears stronger compared to that seen in patients, as a group (Supplementary Figure 3). One 
explanation for this observation is the heterogeneity in disease severity in PSP/CBD, given the 
interaction between [11C]UCB-J, [18F]AV-1451 and disease severity. This can be understood 
in terms of the model set out in Figure 1. The patient group includes those with a strong positive 
correlation (at early stages of disease) and those with negligible correlation (as a consequence 
of more advanced disease). The net result for a group-wise test will be a reduction of the group-
correlation. This is not present in the control group, in whom the level of tau pathology is 
expected to be very much lower (even if present from Alzheimer type tau with high [18F]AV-
1451 affinity).  
To understand the biphasic relationship between molecular pathology and synaptic density, 
one must consider other key players in synaptotoxicity in tauopathies, such as 
neuroinflammation 64. Recent in vivo studies have confirmed the regional co-localisation of 
inflammation and [18F]AV-1451 binding in PSP, including  in many cortical areas 65, in line 
with previous in vivo 66, 67, and post-mortem 68 reports of the tight interplay between 
neuroinflammation and tau accumulation in tauopathies. There is growing evidence that these 
two pathological processes affect synaptic function both independently and synergistically. 
The relationship between tauopathy and synaptic density is even more intriguing when 
considering the change in synaptic density in one region as a function of pathology in another. 
There are strong correlations between [11C]UCB-J binding within the basal ganglia (in 
particular the caudate nucleus and putamen) and [18F]AV-1451 binding in all major cortical 
areas. The reverse association, between subcortical [18F]AV-1451 and cortical [11C]UCB-J 
binding is also observed (Supplementary Figure 4 and 5) but is dismissed here as 
uninterpretable in view of subcortical off-target binding of [18F]AV-1451. The significant 
negative correlation between cortical [18F]AV-1451 binding and synaptic density in the basal 
ganglia could be a reflection of severe disease in the basal ganglia and accumulating pathology 
in the neocortex. In other words, synapses are severely affected in the basal ganglia as one of 
the earliest sites of pathology, with pathology spreading and accumulating in synapse-rich 
areas of the brain, for example the neocortex. A second possible explanation is that loss of 
descending cortico-striatal axons due to cortical pathology, may cause diaschisis, affecting 
subcortical synaptic density even further. Previous analysis of diffusion tensor imaging in 
patients with PSP/CBD have revealed extensive white matter abnormalities (within the main 
association fibres) beyond the degree of cortical atrophy 69, 70 resulting in loss of cortical 
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afferents onto subcortical structures. A third, though not mutually exclusive, potential 
explanation is the weakening of cortical-subcortical functional connectivity resulting from 
dysfunctional synapses rather than synaptic loss, although cortico-subcortical connectivity is 
inferred and was not directly measured in our study. 
Although at a regional level there is a positive correlation between [11C]UCB-J and [18F]AV-
1451 BPND, we are not directly measuring either synaptic function or the synaptotoxic tau 
oligomers. This caveat must be borne in mind when interpreting PET data. It is the preclinical 
models that have shown that oligomers of tau are toxic to synaptic function, even in the absence 
of tau polymers/fibrils 15, 16. By the time tau aggregates are established, oligomers of tau are 
expected cortically, and perhaps interfering with cortical function and the integrity of 
descending axons. 
There are other limitations to our study. First, the low affinity of [18F]AV-1451 for PSP and 
CBD 4R tau. Even though the radioligand recapitulates the distribution of post-mortem 
neuropathology in PSP and CBD, and binds PSP 4R tau, the affinity is very much lower than 
for 3R tau in Alzheimer’s disease. Second, there is well-established off-target binding of 
[18F]AV-1451, particularly within subcortical structures where monoamine oxidase and 
neuromelanin are present. Off-target binding is most prominent in the basal ganglia and 
substantia nigra which we excluded before running the linear mixed model and correlation 
matrix. We included these regions in the detailed descriptive correlation matrices in 
Supplementary Figure 4 and 5 for completeness sake, noting the strong negative correlations 
between cortical [18F]AV-1451 BPND and subcortical [11C]UCB-J BPND. Furthermore, we 
normalised our patient data against that of controls to remove any additional normal levels of 
off-target binding, noting the caveat that the remaining signal in patients may still arise from 
tau and non-tau pathology; there is no evidence to suggest that [18F]AV-1451 shares a common 
binding target with [11C]UCB-J, which has a high specificity for SV2A in previous in vivo  and 
in vitro validation studies 38, 71. Third, we note that in PET studies of neurodegeneration with 
atrophy, grey matter volume loss can affect the interpretation of PET signals. However, 
synaptic loss in PSP and CBD occurs even in areas of the brain without discernible atrophy on 
MRI 7, 8. Nonetheless, we used a stringent partial volume correction method (GTM) to 
minimise the effect of atrophy on our ligand cross-correlations. Of note, our data without partial 
volume correction yield similar results in all the main analyses (Supplementary Figures 2 and 
5). Fourth, although the sample size is small, it is adequately powered in view of the large 
effect sizes seen. However, subtler relationships with phenotypic variants of PSP and CBS, 
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would require larger studies. Additionally, clinical diagnostic criteria for PSP-Richardson’s 
syndrome and amyloid negative CBS (here called CBD) were used to select a clinical cohort 
with likely a 4R-tauopathy as the underlying pathological diagnosis. Whilst both PSP-
Richardson’s syndrome and amyloid negative corticobosal syndrome are highly correlated 
with a 4R-tauopathy at post-mortem, both from our local brain bank and internationally 26, 27, 
72, other pathologies are possible, and so are coexistent pathologies that may synergistically 
contribute to neurodegeneration 73. Neuropathological correlates, to test the correlations 
between phenotype and pathology, and between in vivo-to-post-mortem measures of synaptic 
density, as well as tau-to-synapse correlations would be useful but are not yet available for our 
cohort. Lastly, the cross-sectional design of this study limits the interpretation of the dynamic 
relationship between pathology and synaptic loss. Although we include patients at various 
stages of their illness, a longitudinal design is necessary to test the dynamic relationship we 
propose, and the mediation of synaptic loss by progressive tauopathy. 
In conclusion, we demonstrate a widespread positive association between [18F]AV-1451 and 
[11C]UCB-J binding in patients with symptomatic PSP and amyloid-negative corticobasal 
syndromes. Individual variability in this association correlates with disease severity. The 
complex relationship between molecular pathology, including but not exclusive to tau, and 
synaptic density may explain changes in cognitive and motor physiology. We hope that these 
insights will inform the design of new clinical trials to arrest PSP and CBD.
Page 15 of 40








ab282/6353021 by guest on 26 August 2021
Acknowledgements
The authors thank the research participants and caregivers, the staff at the Wolfson Brain 
Imaging Centre, and at the Cambridge Centre for Parkinson-Plus. We thank the NIHR 
Cambridge Biomedical Research Centre for support. We thank UCB Pharma, and Avid (Lilly) 
for providing the precursor for [11C]UCB-J and [18F]AV-1451 synthesis, respectively. NH and 
JBR had full access to all the data in the study and take responsibility for the integrity of the 
data and the accuracy of the data analysis.  The view expressed are those of the authors and not 
necessarily those of the NIHR or the Department of Health and Social Care. For the purpose 
of open access, the author has applied a CC BY public copyright licence to any Author 
Accepted Manuscript version arising from this submission.
Funding
The study was funded by the Wellcome Trust (220258), Cambridge Centre for Parkinson-Plus 
(RG95450); the National Institute for Health Research Cambridge Biomedical Research Centre 
(BRC-1215-20014); the PSP Association (“MAPT-PSP” study), and the Association of British 
Neurologists, Patrick Berthoud Charitable Trust (RG99368). 
Competing interests
James B Rowe serves as an associate editor to Brain and is a non-remunerated trustee of the 
Guarantors of Brain, Darwin College and the PSP Association (UK). He provides consultancy 
to Asceneuron, Biogen, UCB and has research grants from AZ-Medimmune, Janssen, Lilly as 
industry partners in the Dementias Platform UK. John T. O’Brien has no conflicts related to 
this study. Unrelated to this work he has received honoraria for work as DSMB chair or member 
for TauRx, Axon, Eisai, has acted as a consultant for Roche, has received research support 
from Alliance Medical and Merck. TR has received honoraria from Biogen and the National 
Institute for Health and Clinical Excellence (NICE). No other conflict of interest is reported by 
other authors.
Page 16 of 40








ab282/6353021 by guest on 26 August 2021
References
1. Bigio EH, Vono MB, Satumtira S, et al. Cortical synapse loss in progressive 
supranuclear palsy. Journal of Neuropathology and Experimental Neurology2001. p. 403-
410.
2. Lipton AM, Munro Cullum C, Satumtira S, et al. Contribution of asymmetric synapse 
loss to lateralizing clinical deficits in frontotemporal dementias. Archives of Neurology: 
American Medical Association; 2001. p. 1233-1239.
3. Clare R, King VG, Wirenfeldt M, Vinters HV. Synapse loss in dementias. J Neurosci 
Res. Aug 1 2010;88(10):2083-90. doi:10.1002/jnr.22392
4. DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer's 
disease: Correlation with cognitive severity. Annals of Neurology: John Wiley & Sons, Ltd; 
1990. p. 457-464.
5. Terry RD, Masliah E, Salmon DP, et al. Physical basis of cognitive alterations in 
alzheimer's disease: Synapse loss is the major correlate of cognitive impairment. Annals of 
Neurology: Wiley-Blackwell; 1991. p. 572-580.
6. Jacobsen JS, Wu C-C, Redwine JM, et al. Early-onset behavioral and synaptic deficits 
in a mouse model of Alzheimer's disease. Proceedings of the National Academy of Sciences 
of the United States of America. 2006-03-28 00:00:00 2006;103:5161-5166. 
7. Mak E, Holland N, Jones PS, et al. In vivo coupling of dendritic complexity with 
presynaptic density in primary tauopathies. Neurobiology of Aging: Elsevier BV; 2021. p. 
187-198.
8. Holland N, Jones PS, Savulich G, et al. Synaptic Loss in Primary Tauopathies 
Revealed by [11C]UCB-J Positron Emission Tomography. Movement Disorders: John Wiley 
& Sons, Ltd; 2020. p. 1834-1842.
9. Ahmed Z, Cooper J, Murray TK, et al. A novel in vivo model of tau propagation with 
rapid and progressive neurofibrillary tangle pathology: The pattern of spread is determined 
by connectivity, not proximity. Acta Neuropathologica: Springer; 2014. p. 667-683.
10. Liu L, Drouet V, Wu JW, et al. Trans-synaptic spread of tau pathology in vivo. PLoS 
ONE2012. p. e31302.
11. DeVos SL, Corjuc BT, Oakley DH, et al. Synaptic Tau Seeding Precedes Tau 
Pathology in Human Alzheimer's Disease Brain. Frontiers in Neuroscience: Frontiers Media 
S.A.; 2018. p. 267.
12. Polanco JC, Li C, Durisic N, Sullivan R, Götz J. Exosomes taken up by neurons 
hijack the endosomal pathway to spread to interconnected neurons. Acta neuropathologica 
Page 17 of 40








ab282/6353021 by guest on 26 August 2021
communications: BioMed Central; 2018. p. 10.
13. Gibbons GS, Lee VMY, Trojanowski JQ. Mechanisms of Cell-to-Cell Transmission 
of Pathological Tau: A Review. JAMA Neurol. Jan 1 2019;76(1):101-108. 
doi:10.1001/jamaneurol.2018.2505
14. Seemiller J, Bischof GN, Hoenig MC, Tahmasian M, van Eimeren T, Drzezga A. 
Indication of retrograde tau spreading along Braak stages and functional connectivity 
pathways. European Journal of Nuclear Medicine and Molecular Imaging: Springer Science 
and Business Media Deutschland GmbH; 2021.
15. Menkes-Caspi N, Yamin HG, Kellner V, Spires-Jones TL, Cohen D, Stern EA. 
Pathological tau disrupts ongoing network activity. Neuron2015. p. 959-966.
16. Kaniyappan S, Chandupatla RR, Mandelkow EM, Mandelkow E. Extracellular low-n 
oligomers of tau cause selective synaptotoxicity without affecting cell viability. Alzheimer's 
and Dementia2017. p. 1270-1291.
17. Jiang S, Wen N, Li Z, et al. Integrative system biology analyses of CRISPR-edited 
iPSC-derived neurons and human brains reveal deficiencies of presynaptic signaling in FTLD 
and PSP. Translational Psychiatry2018. p. 265.
18. The Intersection of Amyloid Beta and Tau at Synapses in Alzheimer's Disease, 82 
Cell Press 756-771 (2014). https://www.cell.com/neuron/pdf/S0896-6273(14)00390-0.pdf
19. Mukaetova-Ladinska EB, Garcia-Siera F, Hurt J, et al. Staging of cytoskeletal and β-
amyloid changes in human isocortex reveals biphasic synaptic protein response during 
progression of Alzheimer's disease. American Journal of Pathology: American Society for 
Investigative Pathology; 2000. p. 623-636.
20. Kopeikina KJ, Polydoro M, Tai HC, et al. Synaptic alterations in the rTg4510 mouse 
model of tauopathy. Journal of Comparative Neurology: J Comp Neurol; 2013. p. 1334-1353.
21. Vanhaute H, Ceccarini J, Michiels L, et al. In vivo synaptic density loss is related to 
tau deposition in amnestic mild cognitive impairment. Neurology2020. p. 
10.1212/WNL.0000000000009818.
22. Coomans EM, Schoonhoven DN, Tuncel H, et al. In vivo tau pathology is associated 
with synaptic loss and altered synaptic function. Alzheimer's Research and Therapy: BioMed 
Central Ltd; 2021.
23. Malpetti M, Kievit RA, Passamonti L, et al. Microglial activation and tau burden 
predict cognitive decline in Alzheimer's disease. Brain: Oxford University Press; 2020. p. 
1588-1602.
24. Höglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive 
supranuclear palsy: The movement disorder society criteria. Movement Disorders2017. p. 
Page 18 of 40








ab282/6353021 by guest on 26 August 2021
853-864.
25. Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal 
degeneration. Neurology: American Academy of Neurology; 2013. p. 496-503.
26. Alexander SK, Rittman T, Xuereb JH, Bak TH, Hodges JR, Rowe JB. Validation of 
the new consensus criteria for the diagnosis of corticobasal degeneration. Journal of 
Neurology, Neurosurgery and Psychiatry2014. p. 923-927.
27. Gazzina S, Respondek G, Compta Y, et al. Neuropathological validation of the MDS-
PSP criteria with PSP and other frontotemporal lobar degeneration. bioRxiv: Cold Spring 
Harbor Laboratory; 2019. p. 520510.
28. Dickson DW, Kouri N, Murray ME, Josephs KA. Neuropathology of frontotemporal 
lobar degeneration-tau (FTLD-tau). J Mol Neurosci. Nov 2011;45(3):384-9. 
doi:10.1007/s12031-011-9589-0
29. Kovacs GG, Lukic MJ, Irwin DJ, et al. Distribution patterns of tau pathology in 
progressive supranuclear palsy. Acta Neuropathol. Aug 2020;140(2):99-119. 
doi:10.1007/s00401-020-02158-2
30. Zhou L, McInnes J, Wierda K, et al. Tau association with synaptic vesicles causes 
presynaptic dysfunction. Nature Communications. 2017/05/11 2017;8(1):15295. 
doi:10.1038/ncomms15295
31. Josephs KA, Whitwell JL, Tacik P, et al. [18F]AV-1451 tau-PET uptake does 
correlate with quantitatively measured 4R-tau burden in autopsy-confirmed corticobasal 
degeneration. Acta Neuropathologica. 2016/12/01 2016;132(6):931-933. 
doi:10.1007/s00401-016-1618-1
32. Smith R, Puschmann A, Schöll M, et al. 18F-AV-1451 tau PET imaging correlates 
strongly with tau neuropathology in MAPT mutation carriers. Brain. Sep 2016;139(Pt 
9):2372-9. doi:10.1093/brain/aww163
33. Whitwell JL, Lowe VJ, Tosakulwong N, et al. [18F]AV-1451 tau positron emission 
tomography in progressive supranuclear palsy. Movement Disorders: John Wiley and Sons 
Inc.; 2017. p. 124-133.
34. Ono M, Sahara N, Kumata K, et al. Distinct binding of PET ligands PBB3 and AV-
1451 to tau fibril strains in neurodegenerative tauopathies. Brain. 2017;140(3):764-780. 
doi:10.1093/brain/aww339
35. Ali F, Whitwell JL, Martin PR, et al. [18F] AV-1451 uptake in corticobasal 
syndrome: the influence of beta-amyloid and clinical presentation. Journal of 
Neurology2018. p. 1079-1088.
36. Soleimani-Meigooni DN, Iaccarino L, La Joie R, et al. 18F-flortaucipir PET to 
Page 19 of 40








ab282/6353021 by guest on 26 August 2021
autopsy comparisons in Alzheimer's disease and other neurodegenerative diseases. Brain : a 
journal of neurology: NLM (Medline); 2020. p. 3477-3494.
37. Goodheart AE, Locascio JJ, Samore WR, et al. 18F-AV-1451 positron emission 
tomography in neuropathological substrates of corticobasal syndrome. Brain. Feb 12 
2021;144(1):266-277. doi:10.1093/brain/awaa383
38. Finnema SJ, Nabulsi NB, Eid T, et al. Imaging synaptic density in the living human 
brain. Science Translational Medicine2016.
39. Bajjalieh SM, Peterson K, Linial M, Scheller RH. Brain contains two forms of 
synaptic vesicle protein 2. 1993:2150-2154.
40. Lang AE, Stebbins GT, Wang P, et al. The Cortical Basal ganglia Functional Scale 
(CBFS): Development and preliminary validation. Parkinsonism and Related Disorders: 
Elsevier Ltd; 2020. p. 121-126.
41. Burgos N, Cardoso MJ, Thielemans K, et al. Attenuation correction synthesis for 
hybrid PET-MR scanners: Application to brain studies. IEEE Transactions on Medical 
Imaging2014. p. 2332-2341.
42. Manavaki R, Hong Y, Fryer TD. Brain MRI coil attenuation map processing for the 
GE SIGNA PET/MR: Impact on PET image quantification and uniformity. IEEE Nuclear 
Science Symposium and Medical Imaging Conference Proceedings2019.
43. Avants BB, Epstein CL, Grossman M, Gee JC. Symmetric diffeomorphic image 
registration with cross-correlation: Evaluating automated labeling of elderly and 
neurodegenerative brain. Medical Image Analysis2008. p. 26-41.
44. Rousset OG, Ma Y, Evans AC. Correction for partial volume effects in PET: 
Principle and validation. Journal of Nuclear Medicine1998.
45. Wu Y, Carson RE. Noise reduction in the simplified reference tissue model for 
neuroreceptor functional imaging. J Cereb Blood Flow Metab. Dec 2002;22(12):1440-52. 
doi:10.1097/01.Wcb.0000033967.83623.34
46. Koole M, van Aalst J, Devrome M, et al. Quantifying SV2A density and drug 
occupancy in the human brain using [ 11 C]UCB-J PET imaging and subcortical white matter 
as reference tissue. European Journal of Nuclear Medicine and Molecular Imaging2019. p. 
396-406.
47. Rossano S, Toyonaga T, Finnema SJ, et al. Assessment of a white matter reference 
region for 11C-UCB-J PET quantification. Journal of Cerebral Blood Flow and 
Metabolism2019.
48. Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ. Parametric imaging of 
ligand-receptor binding in PET using a simplified reference region model. NeuroImage: 
Page 20 of 40








ab282/6353021 by guest on 26 August 2021
Academic Press; 1997. p. 279-287.
49. Klunk WE, Koeppe RA, Price JC, et al. The Centiloid project: Standardizing 
quantitative amyloid plaque estimation by PET. Alzheimer's and Dementia: NIH Public 
Access; 2015. p. 1-15.e4.
50. Jack CR, Wiste HJ, Weigand SD, et al. Defining imaging biomarker cut points for 
brain aging and Alzheimer's disease. Alzheimer's and Dementia: NIH Public Access; 2017. p. 
205-216.
51. Tau PET imaging in neurodegenerative tauopathies—still a challenge, 24 Nature 
Publishing Group 1112-1134 (2019). 
52. Jadhav S, Cubinkova V, Zimova I, et al. Tau-mediated synaptic damage in 
Alzheimer's disease. Transl Neurosci. 2015;6(1):214-226. doi:10.1515/tnsci-2015-0023
53. Axonal degeneration in tauopathies: Disease relevance and underlying mechanisms, 
11 572 (2017). 
54. Vogels T, Murgoci AN, Hromádka T. Intersection of pathological tau and microglia 
at the synapse. Acta Neuropathol Commun. Jul 5 2019;7(1):109. doi:10.1186/s40478-019-
0754-y
55. Kovacs GG. Astroglia and Tau: New Perspectives. Frontiers in Aging Neuroscience: 
Frontiers Media SA; 2020. p. 96.
56. Casaletto KB, Zetterberg H, Blennow K, et al. Tripartite Relationship Among 
Synaptic, Amyloid, and Tau Proteins: An In Vivo and Postmortem Study. Neurology. 
2021:10.1212/WNL.0000000000012145. doi:10.1212/WNL.0000000000012145
57. Clavaguera F, Bolmont T, Crowther RA, et al. Transmission and spreading of 
tauopathy in transgenic mouse brain. Nature Cell Biology: Nature Publishing Group; 2009. p. 
909-913.
58. Clavaguera F, Akatsu H, Fraser G, et al. Brain homogenates from human tauopathies 
induce tau inclusions in mouse brain. Proceedings of the National Academy of Sciences of 
the United States of America: National Academy of Sciences; 2013. p. 9535-9540.
59. Cope TE, Rittman T, Borchert RJ, et al. Tau burden and the functional connectome in 
Alzheimer's disease and progressive supranuclear palsy. Brain2018. p. 550-567.
60. Malpetti M, Passamonti L, Jones PS, et al. Neuroinflammation predicts disease 
progression in progressive supranuclear palsy. Journal of Neurology, Neurosurgery & 
Psychiatry2021. p. jnnp-2020-325549.
61. Coyle-Gilchrist ITS, Dick KM, Patterson K, et al. Prevalence, characteristics, and 
survival of frontotemporal lobar degeneration syndromes. Neurology: Lippincott Williams 
and Wilkins; 2016. p. 1736-1743.
Page 21 of 40








ab282/6353021 by guest on 26 August 2021
62. Toledo JB, Zetterberg H, van Harten AC, et al. Alzheimer's disease cerebrospinal 
fluid biomarker in cognitively normal subjects. Brain. Sep 2015;138(Pt 9):2701-15. 
doi:10.1093/brain/awv199
63. Tissot C, L. Benedet A, Therriault J, et al. Plasma pTau181 predicts cortical brain 
atrophy in aging and Alzheimer’s disease. Alzheimer's Research & Therapy. 2021/03/29 
2021;13(1):69. doi:10.1186/s13195-021-00802-x
64. Palleis C, Sauerbeck J, Beyer L, et al. In Vivo Assessment of Neuroinflammation in 
<scp>4‐Repeat</scp> Tauopathies. Movement Disorders2020. p. mds.28395.
65. Malpetti M, Passamonti L, Rittman T, et al. Neuroinflammation and Tau Colocalize 
in vivo in Progressive Supranuclear Palsy. Annals of Neurology: John Wiley and Sons Inc; 
2020. p. 1194-1204.
66. Gerhard A, Trender-Gerhard I, Turkheimer F, Quinn NP, Bhatia KP, Brooks DJ. In 
vivo imaging of microglial activation with [11C]-PK11195 PET progresive supranuclear 
palsy. Movement Disorders: Mov Disord; 2006. p. 89-93.
67. Gerhard A, Watts J, Trender-Gerhard I, et al. In vivo imaging of microglial activation 
with [11C](R -PK11195 PET in corticobasal degeneration. Movement Disorders2004. p. 
1221-1226.
68. Metaxas A, Thygesen C, Briting SRR, Landau AM, Darvesh S, Finsen B. Increased 
Inflammation and Unchanged Density of Synaptic Vesicle Glycoprotein 2A (SV2A) in the 
Postmortem Frontal Cortex of Alzheimer’s Disease Patients. Frontiers in Cellular 
Neuroscience: Frontiers Media S.A.; 2019.
69. Borroni B, Garibotto V, Agosti C, et al. White matter changes in corticobasal 
degeneration syndrome and correlation with limb apraxia. Archives of Neurology: American 
Medical Association; 2008. p. 796-801.
70. Padovani A, Borroni B, Brambati SM, et al. Diffusion tensor imaging and voxel based 
morphometry study in early progressive supranuclear palsy. Journal of Neurology, 
Neurosurgery and Psychiatry: BMJ Publishing Group; 2006. p. 457-463.
71. Nabulsi NB, Mercier J, Holden D, et al. Synthesis and preclinical evaluation of 11C-
UCB-J as a PET tracer for imaging the synaptic vesicle glycoprotein 2A in the brain. Journal 
of Nuclear Medicine2016. p. 777-784.
72. Respondek G, Kurz C, Arzberger T, et al. Which ante mortem clinical features predict 
progressive supranuclear palsy pathology? Movement Disorders2017. p. 995-1005.
73. Robinson JL, Lee EB, Xie SX, et al. Neurodegenerative disease concomitant 
proteinopathies are prevalent, age-related and APOE4-associated. Brain. Jul 1 
2018;141(7):2181-2193. doi:10.1093/brain/awy146
Page 22 of 40








ab282/6353021 by guest on 26 August 2021
Page 23 of 40








ab282/6353021 by guest on 26 August 2021
Figure legends
Figure 1. Schematic diagram illustrating the predicted toxic effect of tau on synaptic 
density as a function of disease severity. At a regional level (A) synaptic density promotes 
the spread of tau within the region, but also from one region to another functionally connected 
region (for example from Region 1 to Region 2 or vice versa; depicted by green arrows). Tau 
is however toxic to synapses, such that at a regional level it leads to a loss of synapses as the 
disease progresses. (B) Tau burden within a given region therefore, depends on a region’s 
baseline synaptic density: for example, Region 3, with a high baseline synaptic density, would 
accumulate more tau in the mild stages of disease (green); but as the disease progresses over 
time, to moderate and advanced stages (yellow and red, respectively), with increasing tau 
accumulation, tau induced synapto-toxicity occurs with a decline in the number of synapses 
within any given region. The prediction would therefore be that, whilst in mild disease the 
degree of tau accumulation is dependent on baseline synaptic density, as the disease progresses 
this relationship breaks down, moving towards a negative association between tau 
accumulation and synaptic density.
Figure 2. The association between normalised synaptic density ([11C]UCB-J) and 
molecular pathology ( [18F]AV-1451) is a function of disease severity. A) Scatter plot of 
[11C]UCB-J BPND and [18F]AV-1451 BPND from 35 patients with PSP-Richardson’s syndrome 
and amyloid-negative CBS (each grey line represents a patient), across 73 regions of interest 
(excluding those with previously reported off-target binding, i.e. basal ganglia and substantia 
nigra) normalised against controls; the dark black line in A depicts the overall fit of the linear 
mixed model, whilst grey lines represent individual patient data. B) The slope for each 
individual (i.e. each grey line in A) is negatively correlated with disease severity (as measured 
with the PSP rating scale); R = -0.41, p < 0.007.
Figure 3. Cortical pathology is negatively correlated with subcortical synaptic density. 
Correlation, in patients, between normalised [18F]AV-1451 BPND in cortical regions (horizontal 
axis) and normalised [11C]UCB-J BPND in cortical and subcortical target regions (vertical axis). 
Negative correlations are observed between cortical [18F]AV-1451 BPND (in frontal, temporal, 
parietal and occipital cortices), and [11C]UCB-J BPND in the caudate nucleus, putamen and 
cerebellum. Only significant correlations (at p < 0.05 uncorrected for multiple comparisons) 
are shown
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Figure 1. Schematic diagram illustrating the predicted toxic effect of tau on synaptic density as a function of 
disease severity.At a regional level (A) synaptic density promotes the spread of tau within the region, but 
also from one region to another functionally connected region (for example from Region 1 to Region 2 or 
vice versa; depicted by green arrows). Tau is however toxic to synapses, such that at a regional level it 
leads to a loss of synapses as the disease progresses. (B) Tau burden within a given region therefore, 
depends on a region’s baseline synaptic density: for example, Region 3, with a high baseline synaptic 
density, would accumulate more tau in the mild stages of disease (green); but as the disease progresses 
over time, to moderate and advanced stages (yellow and red, respectively), with increasing tau 
accumulation, tau induced synapto-toxicity occurs with a decline in the number of synapses within any given 
region. The prediction would therefore be that, whilst in mild disease the degree of tau accumulation is 
dependent on baseline synaptic density, as the disease progresses this relationship breaks down, moving 
towards a negative association between tau accumulation and synaptic density. 
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Figure 2. The association between normalised synaptic density ([11C]UCB-J) and molecular pathology ( 
[18F]AV-1451) is a function of disease severity. A) Scatter plot of [11C]UCB-J BPND and [18F]AV-1451 BPND 
from 35 patients with PSP-Richardson’s syndrome and amyloid-negative CBS (each grey line represents a 
patient), across 73 regions of interest (excluding those with previously reported off-target binding, i.e. basal 
ganglia and substantia nigra) normalised against controls; the dark black line in A depicts the overall fit of 
the linear mixed model, whilst grey lines represent individual patient data. B) The slope for each individual 
(i.e. each grey line in A) is negatively correlated with disease severity (as measured with the PSP rating 
scale); R = -0.41, p < 0.007. 
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Figure 3. Cortical pathology is negatively correlated with subcortical synaptic density.Correlation, in patients, 
between normalised [18F]AV-1451 BPND in cortical regions (horizontal axis) and normalised [11C]UCB-J 
BPND in cortical and subcortical target regions (vertical axis). Negative correlations are observed between 
cortical [18F]AV-1451 BPND (in frontal, temporal, parietal and occipital cortices), and [11C]UCB-J BPND in the 
caudate nucleus, putamen and cerebellum. Only significant correlations (at p < 0.05 uncorrected for 
multiple comparisons) are shown. 
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Table 1 Clinical and Demographics summary
Control PSP CBD F (p)
Gender (M:F) 11:8 10:13 7:5 nsa
Age at [11C]UCB-J PET in years 68.9 (7.1) 71.3 (8.6) 70.9 (7.9) ns
Symptom duration (years) - 3.9 (2.2) 3.9 (2.1) ns
Education (years) 13.6 (2.8) 12 (4.2) 12.6 (2.8) ns
ACE-R total (max. 100) 96.7 (2.7) 80.9 (12.4) 77.5 (17.1) 10.1 (<0.001)
Attention_Orientation (max .18) 17.9 (0.3) 16.3 (1.9) 16.3 (2.3) 4.5 (0.02)
Memory (max .26) 24.6 (1.7) 21.8 (3.8) 20.9 (5.3) 5.3 (0.01))
Fluency (max .14) 12.8 (1.0) 6.6 (3) 7.2 (3.5) 28.0 (<0.001)
Language (max .26) 25.6 (0.8) 23.3 (4.2) 21 (7.2) 5.4 (0.01)
Visuospatial (max .16) 15.7 (0.6) 12.8 (3.4) 12.1 (4.6) 7.5 (0.001)
MMSE (max. 30) 29.4 (1.2) 26.9 (2.6) 25.3 (4.9) 6.7 (0.002)
INECO (max. 30) 25.7 (2.1) 17.2 (5.4) 15.4 (6.5) 17.9 (<0.0001)
PSPRS (max. 100) - 32.7 (8.2) 28.9 (10.0) 3.4 (0.07)
CBFS (max. 120) - 32.7 (15.9) 26.2 (16.2) 0.2 (0.7)
Injected activity (MBq)
[11C]UCB-J 370.7 (114.3) 322.2 (86.0) 320.4 (113.8) ns
[18F]AV-1451 182.3 (10.8) 182.1 (11.4) 186.1 (11.1) ns
[11C]UCB-J and [18F]AV-1451 PET scan 
interval (in days)
157.2 (125.6) 155.9 (129.2) 45.5 (65.7) 4.6 (0.02)
Results are given as mean (and standard deviation) unless otherwise stated. PSP refers to patients with PSP-Richardson’s 
syndrome. CBD refers to amyloid negative corticbasal syndrome. The F-statistic and p-values are derived from ANOVA. ACE-
R: revised Addenbrooke’s Cognitive Examination, MMSE: Mini-mental State Examination, PSPRS: Progressive Supranuclear 
Palsy Rating Scale, CBFS: Cortical Basal ganglia Functional Scale, INECO: Institute of Cognitive Neurology frontal screening 
tool. 
a chi-squared test. ns = non-significant at p<0.05. 
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